المؤلفون: Larcombe R; University of South Australia, Adelaide, South Australia, Australia rebecca.larcombe@sa.gov.au.; Flinders Medical Centre, Bedford Park, South Australia, Australia., Coulthard K; University of South Australia, Adelaide, South Australia, Australia., Eaton V; Flinders Medical Centre, Bedford Park, South Australia, Australia., Tai A; Department Paediatrics, Women's and Children's Hospital, Adelaide, South Australia, Australia.; University of Adelaide, Adelaide, South Australia, Australia., Reuter S; University of South Australia, Adelaide, South Australia, Australia., Ward M; University of South Australia, Adelaide, South Australia, Australia.

المصدر: European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 Jun 21; Vol. 31 (4), pp. 301-306. Date of Electronic Publication: 2024 Jun 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101578294 Publication Model: Electronic Cited Medium: Print ISSN: 2047-9956 (Print) Linking ISSN: 20479956 NLM ISO Abbreviation: Eur J Hosp Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Cystic Fibrosis*/drug therapy , Tobramycin*/administration & dosage , Tobramycin*/blood , Tobramycin*/pharmacokinetics , Drug Monitoring*/methods , Drug Monitoring*/standards , Anti-Bacterial Agents*/administration & dosage , Anti-Bacterial Agents*/pharmacokinetics , Practice Patterns, Physicians'*/standards , Practice Patterns, Physicians'*/trends, Humans ; Canada/epidemiology ; Australia/epidemiology ; New Zealand/epidemiology ; United States ; United Kingdom/epidemiology ; Surveys and Questionnaires ; Ireland/epidemiology